Skip to main content
. 2021 May 20;54(5):1660–1675. doi: 10.1002/jmri.27731

FIGURE 2.

FIGURE 2

Metastases from non‐small cell lung cancer imaged at 3.0 T after administration of 0.1 mmol/kg gadobenate dimeglumine (10 mL; 66‐year‐old male [51.1 kg]; Siemens Skyra; top row) and from endometrial cancer after administration of 0.05 mmol/kg gadobenate dimeglumine (8 mL; 77‐year‐old female [81.1 kg]; Philips Ingenia; Bottom Row). The MR images in the top row (0.1 mmol/kg gadobenate) demonstrate a left parietal lobe mass, isointense on precontrast T1 (a), hypointense on T2 (b), and surrounded by moderate vasogenic edema on T2 FLAIR (c). The postcontrast T1 image (d) clearly delineates an enhancing necrotic mass with well‐defined borders. The mass and its extent are better delineated on the postcontrast T1 image (d) than on the precontrast T1 image (a). The MR images in the bottom row (0.05 mmol/kg gadobenate) show a left cerebellar hemisphere mass, isointense on precontrast T1 (e), hypointense on T2 (f), and with surrounding vasogenic edema on T2 FLAIR (g). The postcontrast T1 image (h) clearly delineates a rim‐enhancing lesion with well‐defined borders. This finding is not well seen on the precontrast T1 image (E). Overall, better delineation of lesion borders, visualization of internal lesion morphology, and lesion contrast enhancement are achieved with the full dose of gadobenate, although the lesion is visualized with half dose gadobenate.